药明康德：前三季度净利润同比下降19.11% 财联社10月28日电，药明康德公告，前三季度实现营业收 入277.02亿元，同比下降6.23%；归属于上市公司股东的净利润65.33亿元，同比下降19.11%。 查看公告原文 ...

Financial Performance - Revenue for the third quarter was RMB 10.46 billion, a decrease of 1.96% year-over-year[5] - Net profit attributable to shareholders for the third quarter was RMB 2.29 billion, down 17.02% year-over-year[5] - Cumulative revenue for the first three quarters of 2024 was RMB 27.70 billion, a decrease of 6.23% year-over-year[5] - Cumulative net profit attributable to shareholders for the first three quarters was RMB 6.53 billion, down 19.11% year-over-year[5] - Basic earnings per share for the third quarter were RMB 0.80, a decrease of 14.89% year-over-year[5] - Weighted average return on equity (ROE) for the third quarter was 4.12%, down 1.47 percentage points year-over-year[6] - Total revenue for the first three quarters of 2024 reached RMB 277.0 billion, a 4.6% increase excluding specific commercial production projects[10] - Total revenue for the first three quarters of 2024 was RMB 27,702,002,254.76, a decrease of 6.2% compared to RMB 29,541,326,133.58 in the same period of 2023[24] - Net profit for the first three quarters of 2024 was RMB 6,601,611,515.97, a decrease of 19.0% compared to RMB 8,148,647,084.33 in the same period of 2023[24] - Operating profit for the first three quarters of 2024 was RMB 7,890,869,263.36, a decrease of 19.5% compared to RMB 9,807,416,477.55 in the same period of 2023[24] - Comprehensive income for the first three quarters of 2024 reached 6,598,257,681.21 yuan, a decrease from 7,604,711,326.21 yuan in the same period of 2023[25] - Basic earnings per share for the first three quarters of 2024 were 2.25 yuan, down from 2.75 yuan in the same period of 2023[25] - Revenue for the first three quarters of 2024 was 27,702,002 thousand yuan, a decrease from 29,541,326 thousand yuan in the same period of 2023[30] - Gross profit for the first three quarters of 2024 was 11,098,161 thousand yuan, down from 12,071,476 thousand yuan in the same period of 2023[30] - Operating profit for the first three quarters of 2024 was 7,842,527 thousand yuan, compared to 9,988,476 thousand yuan in the same period of 2023[30] - Net profit for the first three quarters of 2024 was 6,601,612 thousand yuan, a decrease from 8,148,647 thousand yuan in the same period of 2023[30] - Net profit attributable to parent company holders in Q3 2024 was RMB 2,293,113 thousand, a decrease from RMB 2,763,287 thousand in Q3 2023[32] - Total comprehensive income for the first nine months of 2024 was RMB 6,598,258 thousand, down from RMB 7,604,712 thousand in the same period of 2023[32] - Adjusted non-IFRS net profit attributable to parent company owners for Q3 2024 was RMB 2,973.5 million, compared to RMB 3,072.4 million in Q3 2023, a decrease of 3.2%[37] - Adjusted non-IFRS net profit attributable to parent company owners for the first three quarters of 2024 was RMB 7,345.7 million, compared to RMB 8,167.1 million in the same period of 2023, a decrease of 10.1%[37] - Net profit attributable to parent company owners for Q3 2024 was RMB 2,293.1 million, a decrease of 17.0% compared to RMB 2,763.3 million in Q3 2023[37] - Net profit attributable to parent company owners for the first three quarters of 2024 was RMB 6,532.9 million, a decrease of 19.1% compared to RMB 8,076.4 million in the same period of 2023[37] Business Segment Performance - Revenue from the chemical business (WuXi Chemistry) for the first three quarters was RMB 20.09 billion, down 5.40% year-over-year[8] - Revenue from the testing business (WuXi Testing) for the first three quarters was RMB 4.62 billion, down 4.86% year-over-year[8] - WuXi Biology revenue decreased by 3.64% to RMB 182,594.01 million in Q3 2024[9] - WuXi ATU revenue declined by 17.04% to RMB 85,303.65 million in Q3 2024[9] - WuXi DDSU revenue dropped by 41.01% to RMB 28,970.17 million in Q3 2024[9] - Revenue from global top 20 pharmaceutical companies reached RMB 11.22 billion, up 23.1% excluding specific commercial production projects[10] - TIDES business revenue surged 71.0% to RMB 3.55 billion in the first three quarters of 2024[11] - Small molecule D&M business revenue grew 7.0% to RMB 12.47 billion excluding specific commercial production projects[11] - Clinical CRO and SMO business revenue increased by 3.4% to RMB 1.36 billion in the first three quarters of 2024[13] - Biology business revenue reached RMB 1.83 billion, with new molecule-related business growing 6.0%[13] - CTDMO business revenue was RMB 850 million, impacted by project delays and new order shortages[14] Financial Position - Total assets as of the end of the third quarter were RMB 74.24 billion, an increase of 0.77% compared to the end of the previous year[6] - Total assets as of September 30, 2024, were RMB 74,238,239,875.23, an increase of 0.8% compared to RMB 73,669,349,307.12 at the end of 2023[21] - Total liabilities as of September 30, 2024, were RMB 18,654,997,773.24, an increase of 2.8% compared to RMB 18,151,903,894.38 at the end of 2023[22] - Cash and cash equivalents as of September 30, 2024, were RMB 14,051,541,214.47, an increase of 2.1% compared to RMB 13,764,058,665.13 at the end of 2023[21] - Accounts receivable as of September 30, 2024, were RMB 8,014,543,781.69, an increase of 1.4% compared to RMB 7,901,380,298.53 at the end of 2023[21] - Inventory as of September 30, 2024, was RMB 5,347,792,758.02, an increase of 12.9% compared to RMB 4,736,229,956.28 at the end of 2023[21] - Total equity attributable to owners of the parent company as of September 30, 2024, was RMB 55,173,547,660.38, an increase of 0.1% compared to RMB 55,122,453,910.73 at the end of 2023[22] - Property, plant, and equipment increased to RMB 26,006,848 thousand as of September 30, 2024, compared to RMB 25,844,429 thousand at the end of 2023[33] - Total assets as of September 30, 2024, were RMB 74,238,240 thousand, up from RMB 73,669,349 thousand at the end of 2023[33] - Total liabilities as of September 30, 2024, were RMB 18,654,998 thousand, up from RMB 18,151,904 thousand at the end of 2023[34] - Cash and cash equivalents at the end of September 2024 were RMB 9,271,603 thousand, down from RMB 10,001,039 thousand at the end of 2023[33] Cash Flow - Net cash flow from operating activities for the first three quarters of 2024 was 8,379,092,385.15 yuan, compared to 10,316,787,859.57 yuan in the same period of 2023[27] - Net cash flow from investing activities for the first three quarters of 2024 was -3,194,216,873.13 yuan, an improvement from -5,781,965,276.30 yuan in the same period of 2023[27] - Net cash flow from financing activities for the first three quarters of 2024 was -5,904,884,477.90 yuan, compared to -3,303,987,419.68 yuan in the same period of 2023[29] - Net cash generated from operating activities for the first nine months of 2024 was RMB 8,052,215 thousand, a decrease from RMB 9,847,742 thousand in the same period of 2023[35] - Net cash used in investing activities for the first nine months of 2024 was RMB 2,866,621 thousand, compared to RMB 5,316,765 thousand in the same period of 2023[35] - Net cash used in financing activities for the first nine months of 2024 was RMB 5,905,603 thousand, an increase from RMB 3,300,141 thousand in the same period of 2023[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 385,041[17] - HKSCC NOMINEES LIMITED holds 387,025,502 shares, representing 13.2910% of the total shares[17] - Hong Kong Securities Clearing Company Limited holds 143,295,973 shares, representing 4.9210% of the total shares[17] - G&C VI Limited holds 143,015,795 shares, representing 4.9114% of the total shares[17] - G&C IV Hong Kong Limited holds 104,626,051 shares, representing 3.5930% of the total shares[17] - Beijing Zhongmin Yinfu Investment Management Co., Ltd. holds 87,074,568 shares, representing 2.9903% of the total shares[17] - G&C V Limited holds 73,105,843 shares, representing 2.5106% of the total shares[17] - China Industrial and Commercial Bank Co., Ltd. holds 63,865,186 shares, representing 2.1932% of the total shares[17] - SUMMER BLOOM INVESTMENTS (I) PTE. LTD. holds 60,597,907 shares, representing 2.0810% of the total shares[17] - China Bank Co., Ltd. holds 57,123,648 shares, representing 1.9617% of the total shares[17] Expenses and Other Financial Metrics - Research and development expenses for the first three quarters of 2024 were RMB 954,042,826.94, a decrease of 7.0% compared to RMB 1,025,811,070.87 in the same period of 2023[24] - Equity incentive expenses for Q3 2024 were RMB 79.4 million, a decrease of 49.2% compared to RMB 156.2 million in Q3 2023[37] - Equity incentive expenses for the first three quarters of 2024 were RMB 244.4 million, a decrease of 49.1% compared to RMB 480.6 million in the same period of 2023[37] - Exchange rate fluctuation-related losses for Q3 2024 were RMB 629.8 million, compared to a gain of RMB 18.3 million in Q3 2023[37] - Exchange rate fluctuation-related losses for the first three quarters of 2024 were RMB 658.7 million, compared to a gain of RMB 354.8 million in the same period of 2023[37] - Amortization of intangible assets from acquisitions for Q3 2024 was RMB 13.3 million, a decrease of 10.1% compared to RMB 14.8 million in Q3 2023[37] - Amortization of intangible assets from acquisitions for the first three quarters of 2024 was RMB 40.3 million, a decrease of 6.9% compared to RMB 43.3 million in the same period of 2023[37]

关于注销 2024 年第三次已回购股份暨股份变动的公告 证券代码：603259 证券简称：药明康德 公告编号：临 2024-072 无锡药明康德新药开发股份有限公司 三、 回购期间相关主体买卖股票情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/11 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 | 9 | 11 | 日~2024 | 年 | 12 月 | 10 | 日 | | 预计回购金额 | 亿元~10 10 | | 亿元 | | | | | | | 回购价格上限 | 61.02 元/股 | | | | | | | | | 回购用途 | □减少注册资本 | | √为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 股 23,934,621 | | | | | | | | | 实际回购股数占总股本比例 | ...

无锡药明康德新药开发股份有限公司 证券代码：603259 证券简称：药明康德 公告编号：临 2024-071 关于认购私募基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 投资概述 2024 年 10 月 25 日，无锡药明康德新药开发股份有限公司（以下简称"本 公司"）全资子企业 WuXi PharmaTech Healthcare Fund I L.P.（以下简称"WuXi Fund I"）与 August Global Partners Pte. Ltd.（以下简称"管理公司"或"AGP"） 签署 Subscription Agreement（以下简称"认购协议"），约定由 WuXi Fund I 认 缴 AGP Healthcare Fund VCC（以下简称"投资基金"）1,000 万新加坡元的投资 基金份额（以下简称"本次投资"），约占已募集投资基金份额的 7.66%（WuXi Fund I 所持投资基金份额比例将随投资基金后续募集金额增加而进一步稀释）。 截至本公告日，WuXi ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告及當中所述上市文件僅按香港聯合交易所有限公司證券上市規則（「上市規則」）規定 刊發以供參考，並不構成任何證券的出售要約或招攬購買要約。本公告或當中所述任何內容 （包括上市文件）概非任何合約或承諾的基礎。謹此說明，刊發本公告及當中所述上市文件不 應視為根據發行人（定義見下文）或其代表就香港法例第32章《公司（清盤及雜項條文）條例》而 言刊發的招股章程發售證券，亦並不構成就香港法例第571章《證券及期貨條例》而言邀請公 眾人士訂立或要約訂立協議收購、處置、認購或包銷證券的廣告、邀請或文件。 本公告並非在美國出售發行人證券的要約，亦非招攬購買發行人證券的要約。本公告所述證 券並無亦不會根據1933年《美國證券法》（經修訂）（「證券法」）或美國任何州的證券法登記，且 不得在美國境內發售或出售，惟根據《美國證券法》豁免或在毋須遵守《美國證券法》的交易中 進行者除外。本公告及其所載資料不得直接或間接於或向美國分 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-069 无锡药明康德新药开发股份有限公司 无锡药明康德新药开发股份有限公司（以下简称"本公司"）及其全资子公 司 WuXi AppTec (HongKong) Limited（药明康德（香港）有限公司，以下简称"药 明香港"）已向香港联合交易所有限公司申请批准由药明香港发行并由本公司无 条件及不可撤销地担保的 5 亿美元于 2025 年到期之零息有担保可转换债券（以 下简称"可转债"）的上市及交易。可转债仅可以债券发行的方式向《香港联合 交易所有限公司证券上市规则》第 37 章所规定的专业投资者发行。预计可转债 上市及交易的批准将于 2024 年 10 月 22 日生效。 特此公告。 无锡药明康德新药开发股份有限公司董事会 2024 年 10 月 22 日 1 关于 5 亿美元于 2025 年到期之零息有担保可转换债券 在香港联合交易所有限公司上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

无锡药明康德新药开发股份有限公司（以下简称"本公司"）全资子公司 WuXi AppTec (HongKong) Limited（药明康德（香港）有限公司）发行并由本公司无条 件及不可撤销地担保的 5 亿美元于 2025 年到期之零息有担保可转换债券（以下 简称"可转债"）的认购协议中的所有先决条件（具体内容详见本公司于 2024 年 10 月 8 日于上海证券交易所网站（www.sse.com.cn）披露的《关于拟发行 5 亿美 元于 2025 年到期之零息有担保可转换债券的公告》（公告编号：临 2024-065，以 下简称"《公告》"））均已达成，前述本金总金额 5 亿美元的可转债已于 2024 年 10 月 21 日完成发行。 证券代码：603259 证券简称：药明康德 公告编号：临 2024-068 无锡药明康德新药开发股份有限公司 关于完成发行 5 亿美元于 2025 年到期之零息有担保可转换债券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公告》，可转债的初始转股价为每股 H 股 80.02 港元，《 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-070 无锡药明康德新药开发股份有限公司 关于公司对全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：WuXi AppTec (HongKong) Limited（药明康德（香港）有限 公司，以下简称"药明香港"或"被担保人"），为无锡药明康德新药开发股份有 限公司（以下简称"公司"或"担保人"）的全资子公司。 本次担保金额及已实际为药明香港提供的担保余额：公司为药明香港于 2024 年 10 月 21 日完成发行的 5 亿美元于 2025 年到期之零息有担保可转换债券提供 无条件及不可撤销的担保（以下简称"本次担保"）；截至本公告披露日，不包括 本次担保在内，公司已实际为药明香港提供本金不超过 5 亿美元的担保。 本次担保系为全资子公司提供，无设置反担保。 公司无逾期担保事项。 一、担保情况概述 为支持公司全球化能力及产能建设，优化债务结构，加强公司经营现金流， 巩固公司在医药研发服务领域的行业领先地位， ...

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (药明康德) and raises the target price to 67.72 RMB, reflecting reduced uncertainty from the biosecurity bill and growth in backlog orders [2][4][11]. Core Insights - The impact of the biosecurity bill is expected to be limited, with the company's U.S. operations likely to remain stable despite potential legislative changes [2][13]. - WuXi AppTec has a significant capacity advantage over its peers in India and the U.S. in the chemical drug CDMO sector, making it unlikely for foreign competitors to take over market share in the near term [2][10]. - The company's business is poised for recovery, driven by strong growth in its peptide business and an increase in backlog orders, which grew by 22.4% compared to the end of 2023 [2][12][21]. Financial Performance - The projected revenue growth for WuXi AppTec is -4.4% in 2024E, followed by +10.9% in 2025E and +13.2% in 2026E [2][3]. - Adjusted non-IFRS net profit is expected to decline by 8.4% in 2024E, then increase by 11.5% in 2025E and 14.4% in 2026E [2][3]. Market Position - WuXi AppTec's revenue for its chemical segment in 2023 was 4.14 billion USD, significantly higher than the combined revenue of 10 comparable Indian companies, which totaled 3.15 billion USD [21][22]. - The company has a robust R&D and capital expenditure strategy, with its R&D spending far exceeding that of its Indian counterparts, indicating a strong commitment to innovation and capacity expansion [21][22][24]. Growth Drivers - The peptide business has emerged as a key growth engine, with increasing demand for innovative drugs in metabolic disease areas [2][12]. - The anticipated decline in interest rates by the Federal Reserve is expected to boost global early-stage pharmaceutical financing, further enhancing WuXi AppTec's growth prospects [2][12].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2024年10月28日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2024年9月30日止九個月之第三季業績及其發佈。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2024年10月14日 於本公告日期，董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及張朝 暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及馮岱先生。 * 僅供識別 ...